Objective:To investigate the inhibitory effect of recombinant human endostatin(ES)combined with rAd/P53 on transplanted human breast cancer cell MCF-7 in nude mice.Methods:Animal breast cancer model was established by inoculating MCF-7 cells in nude mice.The animals were randomized into control group,ES group,rAd/P53 group,and ES+ rAd/P53 group.The tumor growth was observed in each group and immunohistochemical method was employed to examine the microvessel density(MVD) and the expression of vascular endothelial growth factor(VEGF).Results:Tumor growth was significantly inhibited in all the 3 treatment groups(P

Background and purpose:There is a tendency to treat tumors through multiple genes and multiple targeting but there has been no reports about the therapeutic effect of recombinant human endostatin(ES)combined with rAd/p53 on graft model of human breast cancer.Methods:MCF-7 human breast cancer cells were inoculated in nude mice.Then the nude mice with xenograft tumor were randomized into groups of control,ES,rAd/p53,and ES + rAd/p53,they were treated according to the plan.Diversity of the xenograft tumor volume and side effect was observed.Microvessel density(MVD)and expression of vascular endothelial growth factor(VEGF)were detected by immunohistochemistry.Results:After the administration of ES,rAd/p53,ES + rAd/p53,the growth of tumor was inhibited with the inhibitory rate of 1.75%,43.36% and 58.68%,respectively.Inhibition of tumor growth was significant in Group rAd/p53 and ES + rAd/p53(P0.05).Conclusions:recombinant human endostatin combined with rAd/p53 can greatly inhibit growth of xenograft tumor,and reduce the generation of capillary vessels.

Background and purpose:Multidrug resistance(MDR)is the main obstacle of chemotherapy in the treatment of cancer,and it has been reported that the muted p53 gene is related to MDR.In this study,we explored whether adenovirus mediated p53 gene(Ad-p53)could reverse MDR of human breast cancer and its impacts on the expressions of P-gp,TOPOⅡ and GST-?.Methods:In this study,adriamycin-resistant human breast carcinoma cells(MCF-7/Adr)and its parental cells(MCF-7)were used to determine the effect of Ad-p53.Cck-8 assay was adopted to evaluate the cytotoxicity of adriamycin.Western blot were performed to observe the expression of P-glycoprotein(P-gp),TopoismeraseⅡ(TOPOⅡ)and GST-?.Results:After transfection with 50 MOI Ad-p53,the 50% inhibitory concentration(IC50)of adriamycin to MCF-7/Adr cells was decreased from(4.54?0.91)?g/ml to(0.26?0.11)?g/ml,and the chemosensitivity increased 18.1 times(P

Objective To investigate the biocompatibility between the atelocollagen scaffold and 3D-cultured myocardial cells,and to find out the condition and an optimal biomaterial scaffold that can be applied to 3D-culture myocardial tissue. Methods The primary cultured myocardial cells were purified and then inoculated into the atelocollagen scaffold.The cells in the atelocollagen scaffold were observed by light microscope,scanning electron microscope(SEM) and transmission electron microscope(TEM) at different times(8d,16d,20d). Results On the first day,cardiac cells pulsating together with the atelocollagen scaffold could be detected under the microscope,which were pulsating complex.A plenty of cells in the atelocollagen mesh were observed under the light microscope,and the cells coalesced with the scaffold.The cells were compacted to the scaffold and coalesced with it at three stages under TEM.Those cells were sticked to the atelocollagen scaffold and expanded sufficiently under SEM.On the atelocollagen scaffold surface,these cells coalesced with lamellar.Conclusion The biocompatibility of the atelocollagen scaffold is better for cultured cardiac myocyte.It can be used as a natural material for 3D-cultured cells,and is suitable for 3D-cultured cardiac cells and cardiac tissues.

Minimally invasive cardiac surgeries are the trend in the future. Among them, robotic cardiac surgery is the latest iteration with several key-hole incision, 3-dimentional visualization, and articulated instrumentation of 7 degree of ergonomic freedom for those complex procedures in the heart. In particular, robotic mitral valve surgery, as well as coronary artery bypass grafting, has evolved over the last decade and become the preferred method at certain specialized centers worldwide because of excellent results. Other cardiac procedures are in various stages of evolution. Stepwise innovation of robotic technology will continue to make robotic operations simpler, more efficient, and less invasive, which will encourage more surgeons to take up this technology and extend the benefits of robotic surgery to a larger patient population.